We have therefore now evaluated AXL and GAS6 levels in both tumor tissue and plasma as well as their relation to clinical course in EGFR‐mutated NSCLC patients before treatment with and after the development of resistance to EGFR‐TKIs. This evidence concerns the gene EGFR and neoplasm.